TARAXASTEROL

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C30H50O
Molecular Weight	426.7174
Optical Activity	UNSPECIFIED
Defined Stereocenters	10 / 10
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[H][C@]12CC[C@]3([H])[C@@]4(C)CC[C@H](O)C(C)(C)[C@]4([H])CC[C@@]3(C)[C@]1(C)CC[C@@]5(C)CCC(=C)[C@@H](C)[C@]25[H]

InChI

InChIKey=XWMMEBCFHUKHEX-ZJJHUPNDSA-N

InChI=1S/C30H50O/c1-19-11-14-27(5)17-18-29(7)21(25(27)20(19)2)9-10-23-28(6)15-13-24(31)26(3,4)22(28)12-16-30(23,29)8/h20-25,31H,1,9-18H2,2-8H3/t20-,21-,22+,23-,24+,25-,27-,28+,29-,30-/m1/s1

HIDE SMILES / InChI

Molecular Formula	C30H50O
Molecular Weight	426.7174
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	9 / 10
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/24548765 | https://www.ncbi.nlm.nih.gov/pubmed/25797286

Taraxasterol is a pentacyclic-triterpene and one of the main active components isolated from Taraxacum officinale. It has been reported to have potent anti-inflammatory properties. The anti-inflammatory effects of taraxasterol against LPS-induced acute lung injury may be due to its ability of inhibition of the NF-κB and MAPK signaling. In addition, taraxasterol protected human chondrocytes by inhibiting MMPs, NO and PGE2 production and therefore could be a useful agent for prevention and treatment of osteoarthritis.

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
MAPK signaling pathway 26 Target ID: map04010 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24548765	Inhibitor 8297
NF-kappa B signaling pathway 84 Target ID: map04064 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24548765	Inhibitor 8297

Conditions

Condition	Modality	Targets	Highest Phase	Product
Acute lung injury 20 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24548765	Palliative		Not Provided 504	Unknown Approved Use Unknown
Osteoarthritis 157 Sources: https://www.ncbi.nlm.nih.gov/pubmed/25797286	Preventing		Basic research	Unknown Approved Use Unknown

PubMed

Title	Date	PubMed
[Studies on chemical constituents from Chinese medicinal plant Hemistepta lyrata Bunge].	2001 Jun	12528508
[Constituents of the leaves of Holodiscus discolor (Pursh) Maxim].	2001 Nov	11797197
GC/MS analysis of some bioactive constituents from Carthamus lanatus L.	2003 Sep-Oct	14577634
Identification and determination of triterpenoids in Hieracium pilosella L.	2007 Mar	17461116
Ethnobotanical remarks on Central and Southern Italy.	2007 May 30	17537240
Ethnophytotherapeutical research in the high Molise region (Central-Southern Italy).	2008 Mar 11	18334029
Fruit-surface flavonoid accumulation in tomato is controlled by a SlMYB12-regulated transcriptional network.	2009 Dec	20019811
The identification of ingested dandelion juice in gastric contents of a deceased person by direct sequencing and GC-MS methods.	2009 May	19432748

Patents

Sample Use Guides

In Vivo Use Guide

in mice: Mice were treated with 2.5, 5 and 10 mg/kg of taraxasterol prior to a lethal dose of lipopolysaccharide (LPS) challenge

Route of Administration: Oral

In Vitro Use Guide

Unknown

Substance Class	Chemical Created by `admin` on `Fri Dec 15 18:26:00 UTC 2023` Edited by `admin` on `Fri Dec 15 18:26:00 UTC 2023`
Record UNII	64SK2ERN9P
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

TARAXASTEROL

Common Name

English

LACTUCEROL

Common Name

English

ANTHESTERIN

Common Name

English

(3.BETA.,18.ALPHA.,19.ALPHA.)-URS-20(30)-EN-3-OL

Common Name

English

TARAXASTEROL [MI]

Common Name

English

TARAXAST-20(30)-EN-3.BETA.-OL

Common Name

English

.ALPHA.-LACTUCEROL

Common Name

English

SAUSSUROL

Common Name

English

Code System Code Type Description

EPA CompTox

DTXSID30909815